Depomed Inc. (NASDAQ:DEPO) was up 2.5% during mid-day trading on Monday . The stock traded as high as $19.57 and last traded at $19.45, with a volume of 695,127 shares. The stock had previously closed at $18.97.

Several brokerages have recently weighed in on DEPO. Royal Bank Of Canada reissued a “sector perform” rating and set a $22.00 price target on shares of Depomed in a research report on Monday, May 2nd. Janney Montgomery Scott reissued a “buy” rating and set a $28.00 price target on shares of Depomed in a research report on Wednesday, June 15th. Leerink Swann reissued a “positive” rating on shares of Depomed in a research report on Monday, July 18th. Cantor Fitzgerald reissued a “buy” rating on shares of Depomed in a research report on Wednesday, June 22nd. Finally, Piper Jaffray Cos. cut shares of Depomed from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $21.00 to $18.00 in a research report on Wednesday, July 27th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the company. Depomed has a consensus rating of “Buy” and a consensus target price of $22.62.

The stock has a 50 day moving average price of $19.24 and a 200 day moving average price of $17.28. The firm’s market cap is $1.18 billion.

Depomed (NASDAQ:DEPO) last announced its quarterly earnings results on Thursday, May 5th. The specialty pharmaceutical company reported $0.12 earnings per share for the quarter, missing analysts’ consensus estimates of $0.17 by $0.05. The firm earned $104.60 million during the quarter, compared to analyst estimates of $106.88 million. During the same period in the prior year, the company posted ($0.13) EPS. The firm’s quarterly revenue was up 230.0% on a year-over-year basis. Equities research analysts anticipate that Depomed Inc. will post $1.20 EPS for the current fiscal year.

In other news, VP Thadd M. Vargas sold 15,000 shares of the firm’s stock in a transaction on Monday, May 23rd. The stock was sold at an average price of $20.00, for a total value of $300,000.00. Following the completion of the transaction, the vice president now owns 109,297 shares in the company, valued at $2,185,940. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CFO August J. Moretti sold 5,000 shares of the stock in a transaction on Monday, May 9th. The shares were sold at an average price of $18.00, for a total value of $90,000.00. Following the sale, the chief financial officer now directly owns 22,879 shares in the company, valued at approximately $411,822. The disclosure for this sale can be found here.

Other hedge funds recently bought and sold shares of the company. Foresters Investment Management Company Inc. raised its stake in Depomed by 4.8% in the fourth quarter. Foresters Investment Management Company Inc. now owns 198,000 shares of the specialty pharmaceutical company’s stock worth $3,590,000 after buying an additional 9,000 shares during the last quarter. Rail Splitter Capital Management LLC bought a new stake in Depomed during the fourth quarter worth approximately $3,976,000. Systematic Financial Management LP raised its stake in Depomed by 96.8% in the fourth quarter. Systematic Financial Management LP now owns 153,450 shares of the specialty pharmaceutical company’s stock worth $2,782,000 after buying an additional 75,460 shares during the last quarter. US Bancorp DE raised its stake in Depomed by 106.9% in the fourth quarter. US Bancorp DE now owns 55,393 shares of the specialty pharmaceutical company’s stock worth $1,004,000 after buying an additional 28,622 shares during the last quarter. Finally, Principal Financial Group Inc. raised its stake in Depomed by 4.8% in the fourth quarter. Principal Financial Group Inc. now owns 408,921 shares of the specialty pharmaceutical company’s stock worth $7,414,000 after buying an additional 18,816 shares during the last quarter.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.